内视镜止血设备市场:各市场区隔规模，占有率，法律规章，偿付，介入，2036年为止的预测

内视镜止血装置包括用于治疗胃肠道 (GI) 出血的装置，通常作为第一线治疗。内视镜止血装置通常分为机械装置（夹子、结扎器、缝线、支架）、注射装置（注射针）、热装置（止血探针、止血钳、加热探针、氩气凝固、射频消融、冷冻疗法）和局部装置（止血喷雾剂）。

内视镜止血技术是治疗消化道出血的技术，作为首选治疗方法。内视镜止血的适应症包括各种上、下消化道出血疾病。上消化道出血主要包括消化性溃疡出血、静脉曲张出血，而憩室出血和良性肛门出血是下消化道出血住院最常见的原因。

本报告对全球内视镜止血设备市场进行了详细分析，提供了竞争格局、 SWOT 分析、 2036 年市场预测、区域和国家趋势。

目录

现在上市的内视镜止血设备和竞争情形

• 主要的产业趋势的洞察
• 内视镜止血设备的各市场区隔整体市场收益和2015年～2036年的市场展望
• 各市场区隔的介入总数，台数，平均销售价格，市场价值相关详细资料

世界，地区，各国洞察

• 内视镜止血设备市场SWOT分析
• 内视镜止血设备市场相关竞争动态的洞察和趋势
• 各国医疗制度概要
• 各国偿付政策
• 各国医疗技术相关法规状况

Endoscopic Hemostasis Devices Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036 is built to visualize quantitative and qualitative market trends within Endoscopy Devices therapeutic area.

Endoscopic Hemostasis Devices consists of devices employed in the management of Gastrointestinal (GI) bleeding and often acts as the first line of therapy. Endoscopic Hemostasis Devices are generally classified into mechanical devices (clips, ligation devices, suturing devices, stents), injection devices (injection needles), thermal devices (hemostatic probes, hemostatic forceps, heater probe, argon plasma coagulation, radiofrequency ablation, and cryotherapy) and topical devices (hemostatic spray).

Endoscopic Hemostasis is a technique employed in the management of Gastrointestinal (GI) bleeding and often acts as the first line of therapy. The indications of endoscopic hemostasis technique include various upper and lower gastrointestinal bleeding diseases. Upper GI bleeding mainly includes peptic ulcer bleeding and variceal bleeding while diverticular bleeding and benign anorectal bleeding are the most common etiologies for hospital admissions with lower GI bleeding.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications with intervention volumes. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Endoscopic Hemostasis Devices and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Endoscopic Hemostasis Devices market revenue by segment and market outlooks from 2015-2036.
• Granular data on total Interventions, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Endoscopic Hemostasis Devices market.
• Competitive dynamics insights and trends provided for Endoscopic Hemostasis Devices market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Boston Scientific Corp, ConMed Corp, Wilson-Cook Medical Inc, ERBE Elektromedizin GmbH, Olympus Corp, United States Endoscopy Group Inc, Micro-Tech Nanjing Co Ltd, Integra LifeSciences Holdings Corp, Medline Industries LP, Diversatek Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Endoscopic Hemostasis market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving Endoscopic Hemostasis Devices market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Endoscopic Hemostasis Devices market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Endoscopic Hemostasis Devices market from 2015-2036.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.